{"disease":{"id":"kras-mutation-related-tumors","name":"kras mutation related tumors"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT05136014","title":"Evaluation of the Response to Tyrosine Kinase Inhibitors in Localized Non-small Cell Lung Cancer (NSCLC) Patients With EGFR Mutation in a Patient-derived Organoid Model","phase":"","overall_status":"UNKNOWN","enrollment_count":200,"lead_sponsor_name":"Central Hospital, Nancy, France","has_results":false},{"nct_id":"NCT03597581","title":"A Study of RGX-202-01 (Ompenaclid) as Combination Therapy in RAS Mutant Advanced Colorectal Cancer","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":89,"lead_sponsor_name":"Inspirna, Inc.","has_results":false},{"nct_id":"NCT04560270","title":"CIrculating Tumor DNA for Monitoring Response to First Line Chemotherapy in Unresectable PANcreatic Cancer","phase":"NA","overall_status":"COMPLETED","enrollment_count":69,"lead_sponsor_name":"Poitiers University Hospital","has_results":false},{"nct_id":"NCT07064018","title":"Trial of Single Protein Encapsulated Doxorubicin, SPEDOX-6 in Advanced Malignancies","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":67,"lead_sponsor_name":"University of California, Irvine","has_results":false},{"nct_id":"NCT06456138","title":"Trametinib Plus Anlotinib Combined With Tislelizumab in KRAS-mutant NSCLC","phase":"PHASE1, PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":60,"lead_sponsor_name":"Shanghai Chest Hospital","has_results":false},{"nct_id":"NCT04916236","title":"Combination Therapy of RMC-4630 and LY3214996 in Metastatic KRAS Mutant Cancers","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":24,"lead_sponsor_name":"The Netherlands Cancer Institute","has_results":false},{"nct_id":"NCT04976439","title":"Patogenic Mutation in 5 Genes","phase":"","overall_status":"COMPLETED","enrollment_count":22,"lead_sponsor_name":"Dr Cipto Mangunkusumo General Hospital","has_results":false},{"nct_id":"NCT05631574","title":"Study of Covalent Menin Inhibitor BMF-219 in Adult Patients With KRAS Driven Non-Small Cell Lung Cancer, Pancreatic Cancer, and Colorectal Cancer","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":13,"lead_sponsor_name":"Biomea Fusion Inc.","has_results":false},{"nct_id":"NCT05071183","title":"A Study of Repotrectinib in Combination With Other Anticancer Therapies for the Treatment of Subjects With KRAS-Mutant Solid Tumors","phase":"PHASE1, PHASE2","overall_status":"TERMINATED","enrollment_count":9,"lead_sponsor_name":"Turning Point Therapeutics, Inc.","has_results":true},{"nct_id":"NCT04735068","title":"Binimetinib and Hydroxychloroquine in Patients With Advanced KRAS Mutant Non-Small Cell Lung Cancer","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":9,"lead_sponsor_name":"Abramson Cancer Center at Penn Medicine","has_results":true}],"total":10},"guidelines":[],"source":"Drug Landscape verified database"}